Calithera Biosciences, Inc.
CALADelisted Mar 3, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001496671
Calithera Biosciences, Inc. was delisted on Mar 3, 2023; its insiders filed their last Form 4 on May 26, 2023; 29 institutions reported holding it in 13F filings for Q2 2022, worth $4.44M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 29
- Q2 2022, −26 vs. previous quarter
- 13F value
- $4.44M
- Reported value at the end of Q2 2022
- Superinvestors holding
- 0
- At the end of Q2 2022
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2022
- –
- No comparable prior period
- Net income, FY2022
- -$39.6M
- No comparable prior period
- Free cash flow, FY2022
- -$43.7M
- No comparable prior period
- Revenue, Q4 FY2022
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 6.80K
- Shares sold short
- Change
- −49
- −0.7% vs. previous
- Days to cover
- 7.95
- At average daily volume
Superinvestors holding CALA, Q2 2022
Go to the superinvestors tabNo superinvestor reported holding CALA at the end of Q2 2022.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Calithera Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 (view filing)7:04 PM ET | Jan 27 | 4 days | Pakianathan DeepikaDirector | SSale | −121.3K | $0.3858 | −$46.8K | −100.0%0 after | 2 lots |
| Nov 12, 2021 (view filing) | Nov 10-11 | 2 days | Orford KeithDirector | SSale | −78.2K | $0.8723 | −$68.2K | −54.2%66.1K after | 2 lots |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Molineaux SusanPRESIDENT & CEO | PPurchase | +100.0K | $0.85 | +$85.0K | +21.9%557.2K after | Duplicate filing |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Drachman Jonathan GDirector | PPurchase | +200.0K | $0.86 | +$172.0K | New position200.0K after | |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Molineaux ChristopherSR. VP, DEVELOPMENT | PPurchase | +100.0K | $0.85 | +$85.0K | +21.9%557.2K after | |
| Nov 9, 2021 (view filing) | Nov 9 | Same day | Orford KeithDirector | SSale | −51.8K | $0.84 | −$43.5K | −26.4%144.3K after |
Top 10 13F holders, Q2 2022
See all 29 holdersThe largest institutional positions in Calithera Biosciences, Inc. at the end of Q2 2022; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 464,742 | $1.14M | 0.06% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Primecap Management Co | 420,280 | $1.03M | 0.00% | −116,370−21.7% | ReducedConverted for a 1-for-20 split |
| Citadel Advisors LLC | 211,484 | $520.0K | 0.00% | +11,701+5.9% | AddedConverted for a 1-for-20 split |
| Acadian Asset Management LLC | 155,070 | $382.0K | 0.00% | +56,223+56.9% | AddedConverted for a 1-for-20 split |
| Vanguard Group Inc | 114,417 | $282.0K | 0.00% | +7,578+7.1% | AddedConverted for a 1-for-20 split |
| Renaissance Technologies LLC | 100,700 | $248.0K | 0.00% | +8,025+8.7% | AddedConverted for a 1-for-20 split |
| BlackRock Inc. | 93,391 | $231.0K | 0.00% | −2,909−3.0% | ReducedConverted for a 1-for-20 split |
| TSP Capital Management Group, LLC | – | $131.0K | 0.05% | – | – |
| Alyeska Investment Group, L.P. | 50,000 | $123.0K | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Geode Capital Management, LLC | 29,245 | $71.0K | 0.00% | −225−0.8% | ReducedConverted for a 1-for-20 split |